3,125
Views
3
CrossRef citations to date
0
Altmetric
Urology

A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

, , , , , , , , , , , , , , , & show all
Pages 867-877 | Received 25 Sep 2020, Accepted 12 Feb 2021, Published online: 08 Mar 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Jan Krhut, Barbora Skugarevská, David Míka, Lars Lund & Peter Zvara. (2022) Clinical Utility of β3-Adrenoreceptor Agonists for the Treatment of Overactive Bladder: A Review of the Evidence and Current Recommendations. Research and Reports in Urology 14, pages 167-175.
Read now

Articles from other publishers (2)

Stefan de Vogel, John D. Seeger, Alejandro Arana, Andrea V. Margulis, Lisa J. McQuay, Susana Perez‐Gutthann, Jesper Hallas, Nina Sahlertz Kristiansen, Marie Linder, Ingvild Odsbu, Brandon Suehs, Yihua Xu, Claudia Uribe, Kwame Appenteng & Noah Jamie Robinson. (2024) Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program. Pharmacoepidemiology and Drug Safety 33:5.
Crossref
Cathrine Axfors, Chirag J. Patel & John P.A. Ioannidis. (2023) Published registry-based pharmacoepidemiologic associations show limited concordance with agnostic medication-wide analyses. Journal of Clinical Epidemiology 160, pages 33-45.
Crossref